The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Sildenafil for Oral Suspension had annual sales of USD 65 million in the United States according to IQVIA data (IQVIA MAT Aug 2022).
The primary objective of the ongoing trial is to determine whether ambrisentan can prevent the progression to respiratory failure and reduce the need for mechanical ventilation, among others
Subscribe To Our Newsletter & Stay Updated
